
About Ami organics
Ami organics is a publicly listed company based in Surat (India) founded in 2007. Advanced API intermediates are manufactured for pharmaceutical use. The company has 244 employees. Ami organics has completed 1 acquisition, including Baba Fine Chemicals. Its Indian entity Acutaas Chemicals Limited reported revenue of ₹1,381 Cr. Ami organics offers products and services including Pharmaceutical Intermediates, Speciality Chemicals, Make to Order Products, and Paraben Formulations. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Its competitors include Viyash, Inventys and Blue Jet Healthcare; 2 of its 3 listed competitors have raised funding.
Company details
Founded in 2007 and based in Surat, India, Ami Organics operates in the pharmaceutical sector. Advanced intermediates for APIs and new chemical entities are produced, with clinical and commercial services provided. Certifications held include GMP, ISO 9001:2008, ISO 14001:2004, OHSAS 18001:2007, and SA 8000:2008. Memberships are maintained with Common Effluent Treatment Plant and Toxic Solid Disposal Site facilities.
- Headquarters Surat, India
- Employees 244
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website amiorganics.com
- Social X Facebook
- Legal Name Acutaas Chemicals Ltd
- Market Cap₹32,561 Cr
ACUTAAS · NSE
- Share Price₹3,833.50
-3.61% today
- Revenue₹1,339 Cr
FY 2025-26 · +33.0% YoY
- EBITDA₹480 Cr
Margin 35.9%
- Net Profit₹356 Cr
FY 2025-26 · +124.5% YoY
- P/E (TTM)74.4x
P/B 17.6x
- ROE24.1%
ROCE 32.2%
- Debt / Equity0.02
Interest cover 0.7x
- Employee Count244
- Investments & Acquisitions
Associated legal entities of Ami organics
Ami organics is associated with 2 registered companies on The Company Check; the primary company is Acutaas Chemicals Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Acutaas Chemicals Limited Listed CIN L24100GJ2007PLC051093 | Active | 12 Jun 2007 | Surat, Gujarat | ₹1,381 Cr | 589 | 10 | View details |
| Ami Procure Private Limited CIN U74900GJ2015PTC083220 | Strike Off | 18 May 2015 | Surat, Gujarat | 2 | View details |
Products & Services of Ami organics
Ami organics offers a comprehensive portfolio of products and services, including Pharmaceutical Intermediates, Speciality Chemicals, Make to Order Products, and Paraben Formulations.
Intermediates used in pharmaceutical manufacturing processes.
Advanced chemicals for specialized industrial applications.
Tailored chemical solutions based on client specifications.
Formulated chemicals for preservation in various sectors.
Board of directors of Acutaas Chemicals Limited (Ami organics)
Acutaas Chemicals Limited is the primary company behind Ami organics. The boards of the 2 registered companies of Ami organics currently have 8 directors; the longest-serving is Nareshkumar Ramjibhai Patel, appointed in 2007. 11 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Nareshkumar Ramjibhai Patel DIN 00906232 | Managing Director | 12 Jun 2007 | 19 yrs 5 mo | Acutaas Chemicals Limited, Ami Procure Private Limited |
| Chetankumar Chhaganlal Vaghasia DIN 01375540 | Whole-time director | 12 Jun 2007 | 19 yrs 5 mo | Acutaas Chemicals Limited, Ami Procure Private Limited |
| Girikrishna Maniar DIN 07515981 | Director | 23 Apr 2018 | 8 yrs 6 mo | Acutaas Chemicals Limited |
| Virendra Nath Mishra DIN 07815490 | Whole-time director | 03 Mar 2021 | 5 yrs 8 mo | Acutaas Chemicals Limited |
| Richa Manoj Goyal DIN 00159889 | Director | 01 Apr 2021 | 5 yrs 7 mo | Acutaas Chemicals Limited |
| Hetal Madhukant Gandhi DIN 00106895 | Director | 28 Apr 2021 | 5 yrs 6 mo | Acutaas Chemicals Limited |
| Ram Mohan Lokhande DIN 08117035 | Whole-time director | 08 Feb 2022 | 4 yrs 9 mo | Acutaas Chemicals Limited |
| Anita Bandyopadhyay DIN 08672071 | Director | 08 Feb 2022 | 4 yrs 9 mo | Acutaas Chemicals Limited |
People of Ami organics
6 people are tracked at Ami organics (2 in leadership, 4 in team); the tracked headcount is 244.
| Name | Role | Group |
|---|---|---|
| Managing Director | Leadership | |
| President & Board Of Director - Operations | Leadership | |
Badrish Patel | Senior Executive EHS | Team |
Dhaval Dobariya | Manager EHS | Team |
Satish Revankar | IT Hod/ CIO | Team |
Dharmesh Pipala | Jr. Officer | Team |
Complete people profiles for Ami organics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Ami organics
Ami organics is a publicly listed company on the NSE with ticker symbol ACUTAAS in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 Sep 2021
- Listed onBSE: 543349 · NSE: AMIORG
- Listed entityAcutaas Chemicals Ltd
- Exchange sectorHealth technology
- ISININE00FF01025
- Share price₹3,160.50 (-0.51% on the day) · 2026-10-14
- Market capitalisation₹26,067 Cr
- Price to earnings67.2
- EPS (diluted, trailing year)₹47.00
- Dividend yield0.08%
- Volume (last session)347,242
Financials of Ami organics
Exchange-reported figures of Acutaas Chemicals Limited, the listed company behind Ami organics (NSE: ACUTAAS).
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 1,339 | 1,007 | 717 | 617 | 520 | 341 | 240 |
| Revenue growth | +33.0% | +40.3% | +16.3% | +18.6% | +52.7% | +42.1% | - |
| EBITDA | 480 | 232 | 96.40 | 123 | 105 | 80.16 | 41.00 |
| EBITDA margin | +35.9% | +23.1% | +13.4% | +19.9% | +20.2% | +23.5% | +17.1% |
| Profit before tax | 483 | 216 | 81.89 | 112 | 91.45 | 71.73 | 34.73 |
| Net profit | 356 | 159 | 61.71 | 83.85 | 71.95 | 54.14 | 28.05 |
| Net profit margin | +26.6% | +15.8% | +8.6% | +13.6% | +13.8% | +15.9% | +11.7% |
| EPS (₹) | 43.51 | 19.39 | 11.60 | 22.86 | 19.75 | 17.14 | 26.16 |
| Balance sheet | |||||||
| Total assets | 1,751 | 1,336 | 901 | 598 | 524 | 308 | 174 |
| Net worth | 1,654 | 1,310 | 674 | 594 | 522 | 167 | 112 |
| Total debt | 35.60 | 12.93 | 217 | 3.60 | 0.84 | 137 | 59.42 |
| Cash & bank | 225 | 249 | 53.31 | 58.67 | 99.55 | 2.68 | 3.82 |
| Net working capital | 677 | 598 | 314 | 297 | 300 | 114 | 65.93 |
| Cash flow | |||||||
| Cash from operations | 292 | 118 | 125 | 65.53 | (11.93) | 27.96 | 27.08 |
| Cash from investing | (266) | (224) | (365) | (33.04) | (121) | (101) | (23.94) |
| Cash from financing | 4.10 | 261 | 239 | (12.25) | 140 | 72.11 | 0.19 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 437 | 330 | 433 | 393 | 306 | 207 | 308 | 275 |
| Revenue growth (YoY) | +42.7% | +59.1% | +40.3% | +43.0% | +24.1% | +17.3% | - | - |
| Other income | 5.10 | 1.80 | 11.11 | 4.70 | 9.84 | 15.94 | 5.78 | 1.67 |
| EBITDA | 176 | 113 | 184 | 151 | 95.33 | 50.91 | 84.95 | 68.67 |
| EBITDA margin | +40.3% | +34.3% | +42.4% | +38.3% | +31.1% | +24.6% | +27.5% | +25.0% |
| Depreciation | 12.69 | 9.82 | 9.63 | 9.82 | 8.40 | 8.13 | 7.30 | 6.32 |
| Interest | 1.02 | 1.14 | 1.19 | 0.86 | 0.58 | 0.64 | 0.60 | 0.69 |
| Profit before tax | 167 | 104 | 184 | 145 | 96.19 | 58.08 | 82.83 | 63.33 |
| Tax | 44.22 | 28.92 | 49.52 | 38.44 | 24.32 | 14.07 | 20.12 | 17.89 |
| Net profit | 123 | 74.99 | 134 | 106 | 71.87 | 44.01 | 62.71 | 45.44 |
| EPS (₹) | 15.24 | 9.04 | 16.04 | 13.10 | 8.82 | 5.41 | 7.80 | 11.35 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 1,324 | 990 | 688 | 617 | 520 | 341 | 240 |
| Revenue growth | +33.7% | +44.0% | +11.5% | +18.6% | +52.7% | +42.1% | - |
| EBITDA | 483 | 225 | 75.90 | 123 | 105 | 80.21 | 41.10 |
| EBITDA margin | +36.5% | +22.8% | +11.0% | +19.9% | +20.2% | +23.6% | +17.2% |
| Profit before tax | 493 | 214 | 69.11 | 112 | 91.45 | 71.73 | 34.76 |
| Net profit | 364 | 157 | 59.04 | 83.91 | 72.05 | 54.62 | 28.16 |
| Net profit margin | +27.5% | +15.9% | +8.6% | +13.6% | +13.9% | +16.0% | +11.8% |
| EPS (₹) | 44.73 | 19.49 | 11.84 | 22.87 | 19.75 | 17.14 | 26.16 |
| Balance sheet | |||||||
| Total assets | 1,705 | 1,325 | 879 | 591 | 519 | 305 | 170 |
| Net worth | 1,668 | 1,312 | 675 | 587 | 518 | 164 | 108 |
| Total debt | 32.03 | 11.10 | 203 | 3.36 | 0.84 | 137 | 59.42 |
| Cash & bank | 165 | 241 | 31.94 | 58.61 | 98.92 | 1.56 | 3.27 |
| Net working capital | 609 | 581 | 289 | 295 | 298 | 111 | 61.51 |
| Cash flow | |||||||
| Cash from operations | 305 | 116 | 101 | 55.73 | (9.69) | 26.38 | 27.25 |
| Cash from investing | (334) | (234) | (337) | (20.47) | (122) | (100) | (24.48) |
| Cash from financing | 3.68 | 274 | 235 | (14.44) | 140 | 72.11 | 0.19 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 433 | 322 | 422 | 391 | 305 | 206 | 304 | 271 |
| Revenue growth (YoY) | +41.9% | +56.5% | +38.7% | +44.3% | +25.3% | +20.4% | - | - |
| Other income | 8.05 | 4.48 | 14.55 | 6.34 | 8.97 | 16.02 | 5.69 | 2.17 |
| Total expenses | 250 | 213 | 241 | 237 | 209 | 155 | 220 | 204 |
| EBITDA | 183 | 110 | 181 | 154 | 96.60 | 50.99 | 84.06 | 66.65 |
| EBITDA margin | +42.3% | +34.0% | +43.0% | +39.5% | +31.7% | +24.8% | +27.6% | +24.6% |
| Depreciation | 9.31 | 9.02 | 8.83 | 9.02 | 7.72 | 7.46 | 6.56 | 5.67 |
| Interest | 0.99 | 1.12 | 1.07 | 0.81 | 0.57 | 0.62 | 0.38 | 0.61 |
| Profit before tax | 181 | 104 | 186 | 151 | 97.28 | 58.93 | 82.81 | 62.54 |
| Tax | 45.35 | 28.12 | 48.79 | 39.14 | 24.39 | 14.28 | 19.97 | 17.24 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 437 | 330 | 433 | 393 | 306 | 207 | 308 | 275 |
| Revenue growth (YoY) | +42.7% | +59.1% | +40.3% | +43.0% | +24.1% | +17.3% | - | - |
| Other income | 5.10 | 1.80 | 11.11 | 4.70 | 9.84 | 15.94 | 5.78 | 1.67 |
| EBITDA | 176 | 113 | 184 | 151 | 95.33 | 50.91 | 84.95 | 68.67 |
| EBITDA margin | +40.3% | +34.3% | +42.4% | +38.3% | +31.1% | +24.6% | +27.5% | +25.0% |
| Depreciation | 12.69 | 9.82 | 9.63 | 9.82 | 8.40 | 8.13 | 7.30 | 6.32 |
| Interest | 1.02 | 1.14 | 1.19 | 0.86 | 0.58 | 0.64 | 0.60 | 0.69 |
| Profit before tax | 167 | 104 | 184 | 145 | 96.19 | 58.08 | 82.83 | 63.33 |
| Tax | 44.22 | 28.92 | 49.52 | 38.44 | 24.32 | 14.07 | 20.12 | 17.89 |
| Net profit | 123 | 74.99 | 134 | 106 | 71.87 | 44.01 | 62.71 | 45.44 |
| EPS (₹) | 15.24 | 9.04 | 16.04 | 13.10 | 8.82 | 5.41 | 7.80 | 11.35 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 1,339 | 1,007 | 717 | 617 | 520 | 341 | 240 |
| Revenue growth | +33.0% | +40.3% | +16.3% | +18.6% | +52.7% | +42.1% | - |
| Other income | 41.59 | 16.93 | 7.49 | 4.32 | 2.76 | 1.38 | 2.84 |
| Total expenses | 859 | 775 | 621 | 494 | 415 | 260 | 199 |
| Employee cost | 118 | 83.66 | 63.11 | 48.84 | 41.37 | 21.01 | 12.95 |
| EBITDA | 480 | 232 | 96.40 | 123 | 105 | 80.16 | 41.00 |
| EBITDA margin | +35.9% | +23.1% | +13.4% | +19.9% | +20.2% | +23.5% | +17.1% |
| Depreciation | 35.99 | 26.62 | 16.06 | 12.34 | 10.08 | 4.19 | 3.52 |
| Interest | 3.27 | 6.22 | 5.94 | 2.41 | 6.41 | 5.62 | 5.59 |
| Profit before tax | 483 | 216 | 81.89 | 112 | 91.45 | 71.73 | 34.73 |
| Tax | 126 | 55.75 | 33.20 | 28.88 | 19.50 | 17.72 | 7.29 |
| Net profit | 356 | 159 | 61.71 | 83.85 | 71.95 | 54.14 | 28.05 |
| Net profit margin | +26.6% | +15.8% | +8.6% | +13.6% | +13.8% | +15.9% | +11.7% |
| EPS (₹) | 43.51 | 19.39 | 11.60 | 22.86 | 19.75 | 17.14 | 26.16 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 40.94 | 40.93 | 36.88 | 36.44 | 36.44 | 31.50 | 10.50 |
| Reserves & surplus | 1,613 | 1,269 | 637 | 558 | 486 | 135 | 101 |
| Shareholders' funds (net worth) | 1,654 | 1,310 | 674 | 594 | 522 | 167 | 112 |
| Minority interest | 57.19 | 10.45 | 8.76 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 17.44 | 8.18 | 217 | 3.60 | 0.84 | 108 | 46.51 |
| Unsecured loans | 18.16 | 4.75 | 0.00 | 0.00 | 0.00 | 28.28 | 12.91 |
| Total debt | 35.60 | 12.93 | 217 | 3.60 | 0.84 | 137 | 59.42 |
| Total liabilities | 1,751 | 1,336 | 901 | 598 | 524 | 308 | 174 |
| Assets | |||||||
| Gross block | 862 | 652 | 498 | 298 | 231 | 203 | 97.78 |
| Net block | 745 | 570 | 427 | 259 | 205 | 186 | 85.19 |
| Capital work in progress | 332 | 130 | 125 | 29.80 | 2.96 | 0.20 | 11.71 |
| Investments | 0.20 | 0.20 | 0.20 | 1.65 | 1.71 | 1.43 | 1.73 |
| Inventories | 231 | 180 | 157 | 119 | 112 | 60.36 | 52.34 |
| Sundry debtors | 363 | 290 | 206 | 230 | 164 | 121 | 56.40 |
| Cash & bank balances | 225 | 249 | 53.31 | 58.67 | 99.55 | 2.68 | 3.82 |
| Loans & advances | 62.55 | 72.27 | 79.42 | 49.02 | 54.15 | 32.49 | 8.47 |
| Total current assets | 881 | 792 | 496 | 457 | 430 | 216 | 121 |
| Total current liabilities | 204 | 194 | 182 | 160 | 129 | 102 | 55.10 |
| Net working capital | 677 | 598 | 314 | 297 | 300 | 114 | 65.93 |
| Total assets | 1,751 | 1,336 | 901 | 598 | 524 | 308 | 174 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 185 | 29.70 | 30.53 | 10.30 | 2.68 | 3.82 | 0.50 |
| Net cash from operating activities | 292 | 118 | 125 | 65.53 | (11.93) | 27.96 | 27.08 |
| Net cash from investing activities | (266) | (224) | (365) | (33.04) | (121) | (101) | (23.94) |
| Net cash from financing activities | 4.10 | 261 | 239 | (12.25) | 140 | 72.11 | 0.19 |
| Net change in cash | 30.33 | 156 | (0.83) | 20.24 | 7.61 | (1.14) | 3.33 |
| Closing cash | 225 | 249 | 53.31 | 58.67 | 99.55 | 2.68 | 3.82 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +33.0% | +40.3% | +16.3% | +18.6% | +52.7% | +42.1% | - |
| EBITDA growth | +107.0% | +140.7% | -21.4% | +16.6% | +31.2% | +95.5% | - |
| PBT growth | +123.3% | +164.0% | -27.0% | +22.7% | +27.5% | +106.5% | -1.1% |
| Net income growth | +124.5% | +157.2% | -26.4% | +16.5% | +32.9% | +93.0% | - |
| Revenue CAGR (3Y) | +29.5% | +24.6% | +28.2% | +37.0% | +29.7% | +21.9% | +14.4% |
| EBITDA CAGR (3Y) | +57.7% | +30.2% | +6.3% | +44.1% | +35.7% | +38.0% | +21.0% |
| Profitability & leverage | |||||||
| Net income margin | +26.6% | +15.9% | +6.8% | +13.5% | +13.8% | +15.9% | +11.5% |
| Return on capital employed | +32.2% | +20.1% | +16.1% | +20.4% | +23.5% | +32.1% | +26.0% |
| Return on net worth | +24.1% | +16.2% | +10.7% | +14.9% | +20.9% | +38.8% | +28.3% |
| Debt / equity | 0.02 | 0.12 | 0.17 | 0.00 | 0.20 | 0.70 | 0.58 |
| Long-term debt / equity | 0.00 | 0.06 | 0.09 | 0.00 | 0.11 | 0.33 | 0.22 |
| Interest cover | 0.74 | 3.03 | 7.39 | 2.19 | 6.74 | 7.40 | 14.91 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.77 | 1.75 | 1.80 | 2.33 | 2.40 | 2.27 | 2.54 |
| Inventory turnover | 6.51 | 5.98 | 5.20 | 5.33 | 6.03 | 6.04 | 5.27 |
| Debtors turnover | 4.10 | 4.05 | 3.29 | 3.13 | 3.66 | 3.85 | 3.62 |
| EPS (₹) | 43.51 | 19.39 | 11.60 | 22.86 | 19.75 | 17.14 | 26.16 |
| Dividend per share (₹) | 2.50 | 1.50 | 3.00 | 3.00 | 3.00 | 0.00 | 0.00 |
| Book value per share (₹) | 201.97 | 159.97 | 182.75 | 163.01 | 143.34 | 52.99 | 106.49 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 433 | 322 | 422 | 391 | 305 | 206 | 304 | 271 |
| Revenue growth (YoY) | +41.9% | +56.5% | +38.7% | +44.3% | +25.3% | +20.4% | - | - |
| Other income | 8.05 | 4.48 | 14.55 | 6.34 | 8.97 | 16.02 | 5.69 | 2.17 |
| Total expenses | 250 | 213 | 241 | 237 | 209 | 155 | 220 | 204 |
| EBITDA | 183 | 110 | 181 | 154 | 96.60 | 50.99 | 84.06 | 66.65 |
| EBITDA margin | +42.3% | +34.0% | +43.0% | +39.5% | +31.7% | +24.8% | +27.6% | +24.6% |
| Depreciation | 9.31 | 9.02 | 8.83 | 9.02 | 7.72 | 7.46 | 6.56 | 5.67 |
| Interest | 0.99 | 1.12 | 1.07 | 0.81 | 0.57 | 0.62 | 0.38 | 0.61 |
| Profit before tax | 181 | 104 | 186 | 151 | 97.28 | 58.93 | 82.81 | 62.54 |
| Tax | 45.35 | 28.12 | 48.79 | 39.14 | 24.39 | 14.28 | 19.97 | 17.24 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 1,324 | 990 | 688 | 617 | 520 | 341 | 240 |
| Revenue growth | +33.7% | +44.0% | +11.5% | +18.6% | +52.7% | +42.1% | - |
| Other income | 45.88 | 18.34 | 13.79 | 4.32 | 2.76 | 1.33 | 2.77 |
| Total expenses | 841 | 765 | 612 | 494 | 415 | 260 | 199 |
| Employee cost | 111 | 80.95 | 60.92 | 48.84 | 41.37 | 20.99 | 12.77 |
| EBITDA | 483 | 225 | 75.90 | 123 | 105 | 80.21 | 41.10 |
| EBITDA margin | +36.5% | +22.8% | +11.0% | +19.9% | +20.2% | +23.6% | +17.2% |
| Depreciation | 33.03 | 24.05 | 14.69 | 12.34 | 10.08 | 4.19 | 3.52 |
| Interest | 3.08 | 5.86 | 5.89 | 2.41 | 6.41 | 5.62 | 5.59 |
| Profit before tax | 493 | 214 | 69.11 | 112 | 91.45 | 71.73 | 34.76 |
| Tax | 127 | 54.03 | 25.42 | 28.88 | 19.50 | 17.72 | 7.29 |
| Net profit | 364 | 157 | 59.04 | 83.91 | 72.05 | 54.62 | 28.16 |
| Net profit margin | +27.5% | +15.9% | +8.6% | +13.6% | +13.9% | +16.0% | +11.8% |
| EPS (₹) | 44.73 | 19.49 | 11.84 | 22.87 | 19.75 | 17.14 | 26.16 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 40.94 | 40.93 | 36.88 | 36.44 | 36.44 | 31.50 | 10.50 |
| Reserves & surplus | 1,627 | 1,271 | 638 | 550 | 482 | 132 | 97.48 |
| Shareholders' funds (net worth) | 1,668 | 1,312 | 675 | 587 | 518 | 164 | 108 |
| Secured loans | 0.00 | 0.00 | 203 | 3.36 | 0.84 | 108 | 46.51 |
| Unsecured loans | 32.03 | 11.10 | 0.00 | 0.00 | 0.00 | 28.28 | 12.91 |
| Total debt | 32.03 | 11.10 | 203 | 3.36 | 0.84 | 137 | 59.42 |
| Total liabilities | 1,705 | 1,325 | 879 | 591 | 519 | 305 | 170 |
| Assets | |||||||
| Gross block | 711 | 577 | 410 | 261 | 204 | 177 | 74.77 |
| Net block | 601 | 499 | 357 | 222 | 178 | 161 | 62.18 |
| Capital work in progress | 228 | 130 | 125 | 29.80 | 2.96 | 0.20 | 11.71 |
| Investments | 118 | 67.73 | 67.73 | 33.45 | 33.40 | 33.24 | 27.89 |
| Inventories | 227 | 174 | 151 | 119 | 112 | 60.36 | 52.34 |
| Sundry debtors | 360 | 289 | 213 | 230 | 162 | 119 | 52.51 |
| Cash & bank balances | 165 | 241 | 31.94 | 58.61 | 98.92 | 1.56 | 3.27 |
| Loans & advances | 57.10 | 69.44 | 71.90 | 46.67 | 53.96 | 32.49 | 8.47 |
| Total current assets | 809 | 773 | 468 | 455 | 427 | 213 | 117 |
| Total current liabilities | 200 | 193 | 179 | 160 | 129 | 102 | 55.08 |
| Net working capital | 609 | 581 | 289 | 295 | 298 | 111 | 61.51 |
| Total assets | 1,705 | 1,325 | 879 | 591 | 519 | 305 | 170 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 185 | 29.49 | 30.48 | 9.66 | 1.56 | 3.27 | 0.32 |
| Net cash from operating activities | 305 | 116 | 101 | 55.73 | (9.69) | 26.38 | 27.25 |
| Net cash from investing activities | (334) | (234) | (337) | (20.47) | (122) | (100) | (24.48) |
| Net cash from financing activities | 3.68 | 274 | 235 | (14.44) | 140 | 72.11 | 0.19 |
| Net change in cash | (24.57) | 155 | (0.99) | 20.82 | 8.10 | (1.72) | 2.96 |
| Closing cash | 165 | 241 | 31.94 | 58.61 | 98.92 | 1.56 | 3.27 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +33.7% | +44.0% | +11.5% | +18.6% | +52.7% | +42.1% | - |
| EBITDA growth | +114.5% | +196.6% | -38.1% | +16.6% | +31.1% | +95.2% | - |
| PBT growth | +130.7% | +209.0% | -38.4% | +22.7% | +27.5% | +106.4% | -5.0% |
| Net income growth | +131.9% | +165.8% | -29.6% | +16.5% | +31.9% | +94.0% | - |
| Revenue CAGR (3Y) | +29.0% | +23.9% | +26.4% | +37.0% | +30.2% | +21.9% | +14.4% |
| EBITDA CAGR (3Y) | +57.9% | +28.9% | -1.8% | +44.0% | +35.0% | +38.0% | +21.1% |
| Profitability & leverage | |||||||
| Net income margin | +27.7% | +16.1% | +6.4% | +13.5% | +13.8% | +15.9% | +11.5% |
| Return on capital employed | +32.7% | +19.9% | +13.5% | +20.7% | +23.8% | +32.6% | +26.4% |
| Return on net worth | +24.6% | +16.1% | +9.4% | +15.1% | +21.1% | +39.7% | +29.1% |
| Debt / equity | 0.01 | 0.11 | 0.16 | 0.00 | 0.20 | 0.72 | 0.60 |
| Long-term debt / equity | 0.00 | 0.06 | 0.09 | 0.00 | -8,210.21 | 0.34 | 0.22 |
| Interest cover | 0.68 | 2.91 | 9.62 | 2.18 | 6.74 | 7.39 | 14.87 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 2.06 | 2.01 | 2.05 | 2.65 | 2.73 | 2.70 | 3.31 |
| Inventory turnover | 6.61 | 6.09 | 5.09 | 5.33 | 6.03 | 6.04 | 5.27 |
| Debtors turnover | 4.08 | 3.94 | 3.10 | 3.15 | 3.71 | 3.98 | 3.82 |
| EPS (₹) | 44.73 | 19.49 | 11.84 | 22.87 | 19.75 | 17.14 | 26.16 |
| Dividend per share (₹) | 2.50 | 1.50 | 3.00 | 3.00 | 3.00 | 0.00 | 0.00 |
| Book value per share (₹) | 203.78 | 160.21 | 183.05 | 161.04 | 142.16 | 52.05 | 102.84 |
Investments & Acquisitions by Ami organics
Ami organics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Baba Fine Chemicals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Manufacturer of speciality chemicals | babafinechemicals.com | Noida, India | 2016 | Apr 2023 | $8.31M |
Complete acquisition details for Ami organics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Ami organics
3 dated milestones of Ami organics across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Ami organics is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Baba Fine Chemicals.
Competitors of Ami organics
Ami organics has 3 listed competitors in our database, 2 of them funded. They include Viyash, Inventys and Blue Jet Healthcare.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| viyash.com | 2019 | Hyderabad, India | $120.02M | 277 | APIs and intermediates are manufactured by Viyash as a CDMO. | |
| inventys.in | 2005 | Mumbai, India | $64.34M | 219 | Actives, advanced intermediates, and specialty chemicals are custom manufactured. | |
| bluejethealthcare.com | 1969 | Mumbai, India | 476 | CDMO focused on manufacturing, supplier, and development of intermediates & APIs |
Detailed competitors of Ami organics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ami organics
Websites that share an audience with Ami organics (amiorganics.com).
Websites whose visitors overlap most with Ami organics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| aartipharmalabs.com | 100% | 5.5K | #3,693,630 | View details | |
| anantrajlimited.com | 88% | 11.8K | #2,145,945 | View details |
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Ami organics (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 2,062 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 548 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ami Organics
Complete news archive for Ami organics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ami organics
Ami organics was founded in 2007.
Ami organics is headquartered in Surat, India. It is registered at Surat, Gujarat, India.
Ami organics has 244 employees.
The primary company behind Ami organics, Acutaas Chemicals Limited, reported revenue of ₹1,381 Cr for FY 2026, up 33% year on year.
Founded in 2007 and based in Surat, India, Ami Organics operates in the pharmaceutical sector. Advanced intermediates for APIs and new chemical entities are produced, with clinical and commercial services provided. Certifications held include GMP, ISO 9001:2008, ISO 14001:2004, OHSAS 18001:2007, and SA 8000:2008. Memberships are maintained with Common Effluent Treatment Plant and Toxic Solid Disposal Site facilities.
Ami organics's top competitors include Inventys, Viyash and Blue Jet Healthcare.
Ami organics offers Pharmaceutical Intermediates, Speciality Chemicals, Make to Order Products, and Paraben Formulations.
Yes, Ami organics is publicly traded on NSE under the ticker symbol ACUTAAS.
Ami organics has made 1 acquisition, including Baba Fine Chemicals.
Ami organics is associated with 2 legal entities: Acutaas Chemicals Limited, Ami Procure Private Limited.
The legal entities of Ami organics currently have 11 directors, including Richa Manoj Goyal, Nareshkumar Ramjibhai Patel, Girikrishna Maniar and others.
